Management of Elevated PTH with Hypercalciuria

Initial Diagnostic Evaluation

In patients with elevated PTH and hypercalciuria, the American College of Nephrology recommends evaluating for vitamin D deficiency and dietary calcium adequacy, then adjusting active vitamin D upward and/or reducing phosphate supplements if necessary, to prevent nephrocalcinosis and renal complications 1
Measuring serum calcium levels helps differentiate between primary hyperparathyroidism and secondary hyperparathyroidism, with primary hyperparathyroidism characterized by elevated or high-normal calcium with elevated PTH 2
Checking 25-OH vitamin D levels is crucial, aiming for >20 ng/ml, as vitamin D deficiency commonly causes secondary hyperparathyroidism and can coexist with hypercalciuria, according to the National Kidney Foundation 1
Assessing dietary calcium intake through detailed dietary evaluation is necessary, as low urinary calcium suggests calcium deprivation, but hypercalciuria at 300 mg/24h indicates the opposite problem 1
Evaluating renal function with serum creatinine and eGFR is essential, as chronic kidney disease is a major cause of secondary hyperparathyroidism and influences treatment decisions, as recommended by the American Society of Nephrology 2

For secondary hyperparathyroidism, the primary strategy is to increase active vitamin D and/or decrease phosphate supplements if the patient is currently on them, according to the National Institute of Diabetes and Digestive and Kidney Diseases 1
Supplementing with native vitamin D (cholecalciferol or ergocalciferol) is recommended if 25-OH vitamin D is below 20 ng/ml, as suggested by the Endocrine Society 1
Ensuring adequate dietary calcium intake according to age-related recommendations (adults >24 years: 950 mg/day) is crucial, as recommended by the National Osteoporosis Foundation 1
Reducing or stopping active vitamin D and phosphate supplements is necessary if hypercalciuria persists or worsens despite PTH optimization, to prevent nephrocalcinosis and kidney stones, according to the American College of Nephrology 1

Administering active vitamin D sterols (calcitriol, alfacalcidol, paricalcitol, or doxercalciferol) is recommended to reduce PTH to target range of 150-300 pg/mL, as suggested by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 5
Intermittent intravenous calcitriol is more effective than daily oral calcitriol for lowering PTH, according to the National Kidney Foundation 5
Monitoring serum calcium and phosphorus every 2 weeks for 1 month after initiation or dose adjustment, then monthly, is necessary, as recommended by the American Society of Nephrology 5
Measuring PTH monthly for at least 3 months, then every 3 months once target achieved, is crucial, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 5